Novartis Pharma AG: Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

Pivotal results for efficacy and safety of Cosentyx (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology

Related Keywords

United States ,America ,American ,Isabella Zinck ,Michael Meo ,Rachel Fink Thoma ,Hidradenitis Suppurativa ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Angelika Jahreis ,Alina Levchuk ,Impact Of Psoriatic Disease On Mental Health ,European Academy Of Dermatology ,Clinical Development Excellence ,Twitter ,Novartis Us External Communications ,Novartis ,Exchange Commission ,Novartis Pharmaceuticals Communications ,International Symposium On Sj ,Global Head Development Unit Immunology ,European Academy ,International Symposium ,Severe Hidradenitis Suppurativa ,Primary Endpoint Analysis ,Subtype Clusters ,Exploratory Analysis ,Demonstrates Superiority ,New Onset Moderate ,Severe Plaque Psoriasis Patients ,Isevere Plaque Psoriasis ,Interim Analysis ,Third Doses ,Spondyloarthritis Receiving Secukinumab ,Demonstrates Faster Time ,Complete Urticaria Control ,Chronic Spontaneous Urticaria Compared ,Term Safety ,Chronic Spontaneous Urticaria ,Real World Study ,Chronic Urticaria ,Psoriatic Disease ,Mental Health ,Global Psoriasis ,Real World Patient Journey ,Unmet Needs ,Social Media ,Terrible Toll ,Dharma ,Highlights ,Depth ,Mmunology ,Pipeline ,Novel ,Data ,Pcoming ,Nternational ,Congresses ,